Early augmentation therapy with dextromethorphan in mild to moderate major depressive disorder: A group sequential, response adaptive randomized controlled trial.
Psychiatry research December 1, 2024 Shampa Maji, Archana Mishra, Debadatta Mohapatra et al. 5 citations
Adding 30 mg of dextromethorphan daily to standard SSRI treatment for eight weeks led to significantly greater reductions in depression severity, higher response and remission rates, and better clinical global improvement in patients with mild to moderate major depressive disorder, compared to adding a placebo. The combination was well-tolerated, with adverse events comparable between groups. No significant difference in serum BDNF levels was observed. These results suggest that early augmentation of SSRIs with dextromethorphan may improve clinical outcomes.